Replies to post #37870 on Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

Orphan drug development has several advantages:

It takes just under 5 years from Phase 2 clinical trial to market, as opposed to 6 to 8 years for traditional drug approval
Orphan designations have better odds for approval with an 82% success rate (Phase 2 forward) as opposed to 35% for traditional drugs
Orphan products have attractive profitability given the smaller patient populations, which drive premium pricing and lower cost of sales
Orphan products experience ongoing revenue growth due to steady uptake after launch with chronic, lifetime customers
Orphan products experience significant competitive advantage to being first to market

[ID Supermoney]

Yes but shorten time frame!! They get money selling or ie Tax credits!!

Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA.

Guess who gets tax credits ie BIG PHARM with JV!!

A big win win for them!!

Better than income for big pharm is a tax credit!!

ID

[ID Supermoney]

Forgot also why did they buy out other drug and company for $250 million??

Reason all for tax credits!!

So a buy out here if proven good!! Is huge win!!! for BIG PHARM!!

If drug works for many diseases!!



ID

[Shark Attack]

At least this person knows what's going on.